Literature DB >> 11743639

Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines.

Fei Wu1, Mikio Nishioka, Jiro Fujita, Masayuki Murota, Yuji Ohtsuki, Toshihiko Ishida, Shigeki Kuriyama.   

Abstract

It has been reported that the cytokeratin 19 (CK19) fragment, CYFRA 21-1, is increased in sera of some hepatocellular carcinoma patients. We hypothesized that CYFRA 21-1 might be released directly from hepatocellular carcinoma. To investigate this mechanism, we evaluated expression of CK19 in 8 human cell lines by immunoradiometric assay, Western blotting, immunohistochemistry, and reverse transcriptase-polymerase chain reaction in Chang liver cells, 2 cholangiocarcinoma cell lines, and 5 hepatocellular carcinoma cell lines. Three of 5 hepatocellular carcinoma cell lines released CYFRA 21-1, synthesized CK19 protein and expressed mRNA for CK19, as observed in 2 cholangiocarcinoma cell lines. In contrast, there was no expression of CK19 in Chang liver cells or 2 of 5 hepatocellular carcinoma cell lines. Analysis of genomic DNA for CK19 demonstrated that exon 1 was not amplified in the 3 cell lines not expressing CK19. However, there were no point mutations within exon 1 and the promoter region of CK19 in hepatocellular carcinoma cell lines. Our present study demonstrates that: i) the expression of CK19 was evident in some human hepatocellular carcinoma cell lines, and ii) the expression of mRNA for CK19 was related to the release of CYFRA 21-1. These results partially clarify the mechanism by which some hepatocellular carcinoma cell lines produce CK19 and others do not.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743639

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients.

Authors:  Yan Li; Zhao-You Tang; Bo Tian; Sheng-Long Ye; Lun-Xiu Qin; Qiong Xue; Rui-Xia Sun
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

2.  Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.

Authors:  Tijana Išić; Svetlana Savin; Dubravka Cvejić; Ilona Marečko; Svetislav Tatić; Marija Havelka; Ivan Paunović
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency.

Authors:  Naosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi Nagasaka
Journal:  Liver Cancer       Date:  2018-08-21       Impact factor: 11.740

4.  Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.

Authors:  Catherine Alix-Panabières; Jean-Pierre Vendrell; Monique Slijper; Olivier Pellé; Eric Barbotte; Grégoire Mercier; William Jacot; Michel Fabbro; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2009-06-23       Impact factor: 6.466

5.  Use of Cytokeratin-19 Concentration to Assess Early Recurrence and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma following Radical Resection in Patients with a Low Serum Alpha-Fetoprotein Concentration.

Authors:  Zu-Sen Wang; Wei-Dong Guo; Li-Qun Wu; Xin Yi; Chao Geng; Yu-Jun Li; Ru-Yong Yao
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

6.  Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.

Authors:  Yuan Rong; Hao Chen; Xue-Feng Zhou; Chang-Qing Yin; Bi-Cheng Wang; Chun-Wei Peng; Shao-Ping Liu; Fu-Bing Wang
Journal:  Oncotarget       Date:  2016-02-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.